Berberine
- Generic Name
- Berberine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H18NO4
- CAS Number
- 2086-83-1
- Unique Ingredient Identifier
- 0I8Y3P32UF
- Background
An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal.
- Indication
主要用于志贺菌属、霍乱弧菌等敏感病原菌所致的胃肠炎、细菌性痢疾等肠道感染。
外用用于治疗敏感细菌引起的宫颈糜烂。
- Associated Conditions
- -
- Associated Therapies
- -
A Mechanistic Randomized Controlled Trial on the Cardiovascular Effect of Berberine
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 84
- Registration Number
- NCT03770325
- Locations
- 🇭🇰
Li Ka Shing Faculty of Medicine, Hong Kong, Hong Kong
Comparison of Berberine and Metformin for the Treatment for MS in Schizophrenia Patients
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Tianjin Anding Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03708549
- Locations
- 🇨🇳
Tianjin Anding Hospital, Tianjin, Tianjin, China
Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2019-08-30
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 658
- Registration Number
- NCT03609892
- Locations
- 🇨🇳
Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China
Berberine Effects on Clinical Symptoms and Metabolic Disturbance in Patients With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Tianjin Anding Hospital
- Target Recruit Count
- 65
- Registration Number
- NCT03548155
Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03486496
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 64
- Registration Number
- NCT03378934
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Berberine Treat Metabolic Syndrome in Schizophrenia
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- Tianjin Anding Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT03251716
- Locations
- 🇨🇳
Tianjin Anding Hospital, Tianjin, Tianjin, China
Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis
- Conditions
- Interventions
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 120
- Registration Number
- NCT03198572
- Locations
- 🇨🇳
Department of Endocrinology and Metabolism,Shanghai 6th People's Hospital, Shanghai, Shanghai, China
🇨🇳The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
🇨🇳Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Berberine as Adjuvant Treatment for Schizophrenia Patients
- Conditions
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 113
- Registration Number
- NCT02983188
- Locations
- 🇭🇰
Castle Peak Hospital - The Department of General Adult Psychiatry, Tuen Mun, Hong Kong
Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Registration Number
- NCT02962245
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.